Takeda Pharmaceutical Co. Ltd. ADR (TAK) News
Filter TAK News Items
TAK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TAK News Highlights
- For TAK, its 30 day story count is now at 10.
- Over the past 21 days, the trend for TAK's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG, TSE and CD are the most mentioned tickers in articles about TAK.
Latest TAK News From Around the Web
Below are the latest news stories about TAKEDA PHARMACEUTICAL CO LTD that investors may wish to consider to help them evaluate TAK as an investment opportunity.
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 CountriesOSAKA, Japan & CAMBRIDGE, Mass., September 13, 2023--Takeda (TSE:4502/NYSE:TAK) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries. The new partnerships bring its total contributions to JPY 24.2 billion (Approx. USD 167.5 million) across 29 long-term partnerships. Takeda’s workforce is an integral part of the annual decision-making process as over 24,500 purpose-le |
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s DiseaseOSAKA, Japan & CAMBRIDGE, Mass., September 13, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO® (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with ENTYVIO intravenous (IV). An application for the SC administration of ENTYVIO for the tre |
Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health ChallengeTakeda Canada Inc. ("Takeda") is pleased to announce two winners of the 2023 Takeda Canada Digital Health Innovation Challenge, a competition to identify and support innovative digital health solutions to improve patient outcomes and experiences. |
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic ArthritisOSAKA, Japan & CAMBRIDGE, Mass., September 11, 2023--Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis. The study met its primary endpoint with a greater proportion of patients treated once-daily with TAK-279 achieving at least a 20 |
Google's investment arm leads $210M raise for biotech partnered with Takeda, LillyNimbus Therapeutics LLC has new investment from none other than GV, the investment arm affiliated with Google. |
Generic drugmakers start shipping copies of Takeda's ADHD drug VyvanseDrugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States. The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drugmakers after Takeda's exclusivity over the drug expired on Aug. 24. U.S.-based drugmakers Mallinckrodt and Viatris , UK-based Hikma Pharmaceuticals and Indian drugmaker Sun Pharmaceutical Industries confirmed on Thursday they began shipping their generic versions of the drug, which is also approved for a binge-eating disorder in adults. |
Generics of Vyvanse, Takeda's ADHD drug, get FDA green lightThe U.S. Food and Drug Administration on Monday approved several generics of Vyvanse, a drug for ADHD as well as binge-eating disorder. The Japanese pharma company, whose U.S. headquarters are in Cambridge, previously forecast that competition from generics would drive a 38% year-over-year drop in revenue for the drug. “We’ve planned for it,” U.S. business unit head Julie Kim told the Business Journal earlier this year. |
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. ViatrisIf you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS). Both companies offer attractive dividends, but which one is a better buy right now? Let's take a closer look at their financial performance, growth prospects, valuation, and dividend sustainability to find out. |
2 Ultra-Cheap High-Yield Dividend Stocks to Buy NowDividend stocks can be a port in the storm. Thanks to powerful wealth-building vehicles like dividend reinvestment plans, these stocks can take advantage of the power of both dollar-cost averaging and compounding. Read on to find out more about these two elite dividend stocks. |